Immunotherapy treatments approved for small cell lung cancer: Checkpoint inhibitors
Checkpoint inhibitor drugs approved for first-line (as your first) treatment:
- Imfinzi (durvalumab) – approved for use in limited-stage SCLC following combination chemotherapy and radiation for people who have not experienced progression. It is also approved in combination with chemotherapy for people with extensive-stage SCLC.
-
Tecentriq (atezolizumab) – approved in combination with chemotherapy for people with extensive-stage SCLC. It is also approved for the same uses as a subcutaneous injection (a shot under the skin) under the name Tecentriq Hybreza (atezolizumab with hyaluronidase-tqjs).
Click here for answers to frequently asked questions about immunotherapy for lung cancer.